

In the Claims

Please cancel claims 19-23, 26-29, 31-80, 82-89, 91-96, 98-138, 140, 141, 143, 145-165, 167, 169-176, 178-181, 183, 185-187, 189, 190, 192-194, 196, 198-209, 211-250, 262-289, 291-319, 321-337 and 339.

Please amend claims 25, 30, 139, 142, 144, 166, 251-260 and 338 as shown below.

Please replace all prior versions and listings of claims in this application with the following list of claims.

1. (Original) A method for stimulating an immune response in a subject comprising administering to a subject in need of immune stimulation an agent of Formula I, and an antibody or antibody fragment, in an amount effective to stimulate an immune response.
2. (Original) The method of claim 1, wherein the immune response is antibody dependent cell-mediated cytotoxicity.
3. (Original) The method of claim 1, wherein the antibody or antibody fragment is an antibody.
4. (Original) The method of claim 1, wherein the antibody or antibody fragment is an anti-HER2 antibody.
5. (Original) The method of claim 4, wherein the anti-HER2 antibody is trastuzumab.
6. (Original) The method of claim 1, wherein the antibody or antibody fragment is an anti-CD20 antibody.
7. (Original) The method of claim 6, wherein the anti-CD20 antibody is rituximab.
8. (Original) The method of claim 1, wherein the antibody or antibody fragment is administered in a sub-therapeutic dose.

9. (Original) The method of claim 1, wherein the agent of Formula I is administered in a route of administration different from that of the antibody or antibody fragment.
10. (Original) The method of claim 1, wherein the agent of Formula I is administered orally and the antibody or antibody fragment is administered by injection.
11. (Original) The method of claim 1, wherein the agent of Formula I is administered prior to the antibody or antibody fragment.
12. (Original) The method of claim 11, wherein the agent of Formula I is administered 30 minutes to 8 hours prior to the antibody or antibody fragment.
13. (Original) The method of claim 11, wherein the agent of Formula I is administered 1 to 7 days prior to the antibody or antibody fragment.
14. (Original) The method of claim 1, wherein the agent of Formula I is administered substantially simultaneously with the antibody or antibody fragment.
15. (Original) The method of claim 1, wherein the agent of Formula I is administered after the antibody or antibody fragment.
16. (Original) The method of claim 15, wherein the agent of Formula I is administered 30 minutes to 8 hours after the antibody or antibody fragment.
17. (Original) The method of claim 15, wherein the agent of Formula I is administered 1 to 7 days after the antibody or antibody fragment.
18. (Original) A method for stimulating an immune response in a subject having or at risk of having cancer comprising
administering to a subject in need of immune stimulation an agent of Formula I, and an antigen, in an amount effective to stimulate an antigen-specific immune response.

19. – 23. (Cancelled)

24. (Original) A method for stimulating an immune response in a subject comprising administering to a subject in need of immune stimulation an agent of Formula I, and an antigen, in an amount effective to stimulate an antigen-specific immune response, wherein the agent of Formula I is administered at a concentration of greater than 10^{-8} M.

25. (Currently Amended) The method of claim 1[[or 24]], wherein the subject is a subject having or at risk of developing cancer.

26. – 29. (Cancelled)

30. (Currently Amended) The method of claim 1[[, 18 or 24]], wherein the subject is a subject having or at risk of developing an infectious disease.

31. – 80. (Cancelled)

81. (Original) A method of preventing an infectious disease in a subject at risk of developing an infectious disease comprising identifying a subject at risk of developing an infectious disease, and administering an agent of Formula I to the subject in an amount effective to induce IL-1.

82. – 89. (Cancelled)

90. (Original) A method for stimulating an immune response in a non-immunocompromised subject comprising administering to a subject in need thereof an agent of Formula I, in an amount effective to induce IL-1.

91. – 96. (Cancelled)

97. (Original) A method for stimulating an immune response in an immunocompromised subject comprising administering to a subject in need thereof an agent of Formula I, in an amount effective to induce IL-1.

98. – 138. (Cancelled)

139. (Currently Amended) The method of claim 1[[, 92 or 102]], wherein the antibody or antibody fragment is administered on a first day of a seven day cycle and the agent of Formula I is administered twice a day on day two through day seven.

140. – 141. (Cancelled)

142. (Currently Amended) The method of claim 1[[, 92 or 102]], wherein the antibody or antibody fragment is conjugated to a toxin derived from plant, fungus, or bacteria.

143. (Cancelled)

144. (Currently Amended) The method of claim 1[[, 92 or 102]], wherein the antibody or antibody fragment is conjugated to a chemotherapeutic agent or a radioisotope.

145. – 165. (Cancelled)

166. (Currently Amended) The method of claim 1[[, 92 or 102]], wherein the antibody or antibody fragment is selected from the group consisting of Avastin (bevacizumab), BEC2 (mitumomab), Bexxar (tositumomab), Campath (alemtuzumab), CeaVac, Herceptin (trastuzumab), IMC-C225 (centuximab), LymphoCide (epratuzumab), MDX-210, Mylotarg (gemtuzumab ozogamicin), Panorex (edrecolomab), Rituxan (rituximab), Theragyn (pemtumomab), ZamyI, and Zevalin (ibritumomab tiuxetan).

167. (Cancelled)

168. (Original) A method for treating a subject having or at risk of developing an IFN-responsive condition comprising

administering to a subject in need of such treatment an agent of Formula I in an amount effective to induce a therapeutically or prophylactically effective amount of IL-1 in the subject.

169. – 176. (Cancelled)

177. (Original) A method for treating a subject having or at risk of developing cancer comprising administering to a subject in need of such treatment an enzyme inhibitor selected from the group consisting of a tyrosine kinase inhibitor, a CDK inhibitor, a MAP kinase inhibitor, and an EGFR inhibitor, and an agent of Formula I in an amount effective to inhibit the cancer.

178. – 181. (Cancelled)

182. (Original) A method for treating a subject having or at risk of developing cardiovascular disease comprising

administering to a subject in need of such treatment an agent of Formula I in an amount effective to induce an effective amount of IL-1.

183. (Cancelled)

184. (Original) A method for preventing drug resistance in a subject having an infectious disease comprising

administering to a subject receiving an anti-microbial agent, an agent of Formula I in an amount effective to reduce the risk of resistance to the anti-microbial agent.

185. – 187. (Cancelled)

188. (Original) A method of shortening a vaccination course comprising
administering to a subject in need of immunization an agent of Formula I in an amount
effective to induce an antigen-specific immune response to a vaccine administered in a vaccination
course,
wherein the vaccination course is shortened by at least one immunization.

189. – 190. (Cancelled)

191. (Original) A method of shortening a vaccination course comprising
administering to a subject in need of immunization an agent of Formula I in an amount
effective to induce an antigen-specific immune response to a vaccine administered in a vaccination
course,
wherein the vaccination course is shortened by at least one day.

192. – 194. (Cancelled)

195. (Original) A method for stimulating an immune response in a subject having cancer
comprising
administering to a subject in need of such treatment an agent of Formula I in an amount
effective to stimulate an antigen-specific immune response, prior to and following a therapy selected
from the group consisting of radiation, surgery and chemotherapy.

196. (Cancelled)

197. (Original) A method for stimulating an immune response in a subject at risk of developing
cancer comprising
administering to a subject in need of such treatment an agent of Formula I in an amount
effective to stimulate an antigen-specific immune response.

198. – 209. (Cancelled)

210. (Original) A method for modulating an immune response comprising administering to a subject in need thereof an antibody or an antibody fragment on a first day of a seven day cycle, and administering to the subject an agent of Formula I on day 2 through to day 7 of the seven day cycle.

211. – 250. (Cancelled)

251. (Currently Amended) The method of claim 1, ~~18, 24, 81, 90, 97, 168, 177, 182, 184, 188, 191, 195, 197 or 210~~ wherein the agent of Formula I is an agent of Formula II.

252. (Currently Amended) The method of claim 1, ~~18, 24, 81, 90, 97, 168, 177, 182, 184, 188, 191, 195, 197 or 210~~ wherein the agent of Formula I is an agent of Formula III.

253. (Currently Amended) The method of claim 1, ~~18, 24, 81, 90, 97, 168, 177, 182, 184, 188, 191, 195, 197 or 210~~ wherein the agent of Formula I is selected from the group consisting of L-Val-L-boroPro, L-Met-L-boroPro, and L-Ile-L-boroPro.

254. (Currently Amended) The method of claim 1, ~~18, 24, 81, 90, 97, 168, 177, 182, 184, 191, 195, 197 or 210~~, wherein the agent of Formula I is in a cyclic form.

255. (Currently Amended) The method of claim 1, ~~18, 24, 177, 182, 188, 191, 195, 197 or 210~~, wherein the agent of Formula I is administered in an amount that increases lymphoid tissue levels of IL-1, G-CSF or IL-8.

256. (Currently Amended) The method of claim 1, ~~18, 24, 177, 182, 184, 188, 191, 195, 197 or 210~~, wherein the agent of Formula I is administered in an amount that does not increase serum IL-1 levels.

257. (Currently Amended) The method of claim 1, ~~18, 24, 81, 90, 97, 168, 177, 182, 184, 188, 191, 195, 197 or 210~~, wherein the IL-1 is IL-1 α or IL-1 β .

258. (Currently Amended) The method of claim 1, ~~18, 24, 81, 90, 97, 168, 177, 182, 184, 188, 191, 195, 197 or 210~~, wherein the subject is otherwise free of symptoms calling for hematopoietic stimulation.

259. (Currently Amended) The method of claim 1, ~~18, 24, 81, 90, 97, 168, 177, 182, 184, 188, 191, 195, 197 or 210~~, wherein the agent of Formula I is administered on a routine schedule.

260. (Currently Amended) The method of claim 1, ~~18, 24, 81, 90, 97, 168, 177, 182, 184, 188, 191, 195, 197 or 210~~, wherein the subject is HIV negative.

261. (Original) A composition comprising
an effective amount of an agent of Formula I and an antibody or antibody fragment.

262. – 289. (Cancelled)

290. (Original) A composition comprising
an effective amount of an agent of Formula I and a cancer antigen.

291. – 319. (Cancelled)

320. (Original) A composition comprising
an effective amount of an agent of Formula I and a microbial antigen,
wherein the agent of Formula I is formulated for administration at a dose of greater than 10^8 M.

321. – 337. (Cancelled)

338. (Currently Amended) The method of claim 1, ~~18, 24, 81, 90, 97, 168, 177, 182, 184, 188, 191, 195, 197 or 210~~, wherein the agent of Formula I is at least 96% pure L-isomer.

339. (Cancelled)